Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2010

Open Access 01-12-2010 | Research

Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer

Authors: Yanyan Zhou, Nanxiang Zhou, Weiyi Fang, Jirong Huo

Published in: Diagnostic Pathology | Issue 1/2010

Login to get access

Abstract

Background

Hepatoma-derived growth factor (HDGF) is involved in the hepatocarcinogenesis. In this study, we investigated the HDGF expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic features, including the survival of patients with HCC. Furthermore, we examined the biological processes regulated by HDGF during the development of using HepG2 cell line as a model system.

Methods

we used immunohistochemistry to compare HDGF protein expression in HCC and normal liver tissues and further analyze the HDGF protein expression in clinicopathologically characterized 137 HCC cases. We stably knocked down the endogenous expression level of HDGF in HepG2 cells with specific shRNA-expressing lentiviral vector. Following the successful establishment of stable cells, we examined in vitro cell growth by MTT assay, anchorage-independent growth by soft-agar colony formation assay and cell migration/invasion by transwell and boyden chamber assay. And in addition, we also investigated the in vivo tumor growth by xenograft transplantation of HepG2 cells into nude mice.

Results

Protein expression level of HDGF was markedly higher in HCC tissues than that in the normal liver tissues(P = 0.011). In addition, high expression of HDGF protein was positively correlated with T classification(p < 0.001), N classification (p < 0.001), and clinical stage (p < 0.001) of HCC patients. Patients with higher HDGF expression showed a significantly shorter overall survival time than did patients with low HDGF expression. Multivariate analysis suggested that HDGF expression might be an independent prognostic indicator(p < 0.001) for the survival of patients with HCC. HDGF-specific shRNA (shHDGF) successfully knocked down its endogenous expression in HepG2 cells. Compared to the parental and control shRNA-transfected (shCtrl) HepG2 cells, the shHDGF cells exhibited significantly reduced in vitro cell growth, anchorage-independent growth, cell migration and invasion (p < 0.05). In vivo, the xenograft transplants from shHDGF cells gave rise to much smaller tumors as compared to those from shCtrl cells.

Conclusion

High HDGF expression is associated with poor overall survival in patients with HCC. Down-regulation of HDGF inhibits the growth, anchorage-independent growth, migration and invasion of HepG2 cells.
Appendix
Available only for authorised users
Literature
1.
Schutte K, Bornschein J, Malfertheiner P: Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis. 2009, 27: 80-92.PubMed
2.
Li D, Mallory T, Satomura S: AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001, 313: 15-19. 10.1016/S0009-8981(01)00644-1.CrossRefPubMed
3.
Blum HE, Spangenberg HC: Hepatocellular carcinoma: an update. Arch Iran Med. 2007, 10: 361-371.PubMed
4.
Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, Yamamoto H, Kishimoto T: Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem. 1994, 269: 25143-25149.PubMed
5.
Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, Yamamoto H, Sato J, Kishimoto S: Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 1989, 183: 273-284. 10.1016/0009-8981(89)90361-6.CrossRefPubMed
6.
Everett AD, Stoops T, McNamara CA: Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem. 2001, 276: 37564-37568. 10.1074/jbc.M105109200.CrossRefPubMed
7.
Enomoto H, Yoshida K, Kishima Y, Kinoshita T, Yamamoto M, Everett AD, Miyajima A, Nakamura H: Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology. 2002, 36: 1519-1527.CrossRefPubMed
8.
Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, Funamoto M, Ito H, Everett AD, Hada T, Kawase I: Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003, 94: 1034-1041. 10.1111/j.1349-7006.2003.tb01397.x.CrossRefPubMed
9.
Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A: Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol. 2004, 286: L1194-1201. 10.1152/ajplung.00427.2003.CrossRefPubMed
10.
Matsuyama A, Inoue H, Shibuta K, Tanaka Y, Barnard GF, Sugimachi K, Mori M: Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer. Cancer Res. 2001, 61: 5714-5717.PubMed
11.
Everett AD: Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev Dyn. 2001, 222: 450-458. 10.1002/dvdy.1204.CrossRefPubMed
12.
13.
Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D, Scotlandi K, Knuutila S: Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer. 2009, 9: 17-10.1186/1471-2407-9-17.PubMedCentralCrossRefPubMed
14.
Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, Chen CH, Lu SN, Lee CM, Changchien CS, Hu TH: Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer. 2007, 121: 1059-1065. 10.1002/ijc.22803.CrossRefPubMed
15.
Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H: Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol. 2006, 13: 159-167. 10.1245/ASO.2006.11.035.CrossRefPubMed
16.
Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K: Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep. 2005, 13: 1075-1080.PubMed
17.
Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L: Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2004, 22: 3230-3237. 10.1200/JCO.2004.02.080.CrossRefPubMed
18.
Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, Aozasa K, Uyama H, Nakamura H, Monden M: Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol. 2007, 14: 2141-2149. 10.1245/s10434-007-9369-9.CrossRefPubMed
19.
Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, Kawase I, Hayashi N, Monden M: Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res. 2006, 12: 6043-6048. 10.1158/1078-0432.CCR-06-1064.CrossRefPubMed
20.
Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, Xie W, Li Z, Zhao Y, Wang E, Marincola FM, Yao K: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008, 6: 32-10.1186/1479-5876-6-32.PubMedCentralCrossRefPubMed
21.
Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, Xie S, Xiao G, Li X, Yao K, Fang W: Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol Cancer. 2010, 9: 78-10.1186/1476-4598-9-78.PubMedCentralCrossRefPubMed
22.
Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, Yao K, Wu B, Fang W: Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010, 10: 270.
23.
Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008, 4;6: 55-10.1186/1479-5876-6-55.CrossRef
24.
Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006, 6: 674-687. 10.1038/nrc1934.CrossRefPubMed
25.
Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F: JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer. 2009, 8: 64-10.1186/1476-4598-8-64.PubMedCentralCrossRefPubMed
26.
Wei W, Chua MS, Grepper S, So SK: Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer. 2009, 8: 76-10.1186/1476-4598-8-76.PubMedCentralCrossRefPubMed
27.
Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F: Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer. 2008, 7: 21-10.1186/1476-4598-7-21.PubMedCentralCrossRefPubMed
28.
Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, Feitelson MA: Increased expression of ErbB-2 in liver is associated with hepatitis B × antigen and shorter survival in patients with liver cancer. Int J Cancer. 2009, 125 (8): 1894-1901. 10.1002/ijc.24580.PubMedCentralCrossRefPubMed
29.
Csepregi A, Ebert MP, Rocken C, Schneider-Stock R, Hoffmann J, Schulz HU, Roessner A, Malfertheiner P: Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer. 2010, 10: 317-10.1186/1471-2407-10-317.PubMedCentralCrossRefPubMed
30.
Tung EK, Wong CM, Yau TO, Lee JM, Ching YP, Ng IO: HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. Int J Cancer. 2009, 124: 1811-1819. 10.1002/ijc.24115.CrossRefPubMed
31.
Chan DW, Lee JM, Chan PC, Ng IO: Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer. 2008, 123: 1043-52. 10.1002/ijc.23634.CrossRefPubMed
32.
Everett AD, Bushweller J: Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets. 2003, 4: 367-371. 10.2174/1389450033490975.CrossRefPubMed
33.
Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M, Kuroda T, Ito H, Yoshizaki K, Nakamura H: Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem. 2002, 277: 10315-10322. 10.1074/jbc.M111122200.CrossRefPubMed
34.
Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, Zheng S, Zhu Y: Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 2008, 99: 2120-2127. 10.1111/j.1349-7006.2008.00928.x.CrossRefPubMed
35.
Zhou Z, Yamamoto Y, Sugai F, Yoshida K, Kishima Y, Sumi H, Nakamura H, Sakoda S: Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem. 2004, 279: 27320-27326. 10.1074/jbc.M308650200.CrossRefPubMed
36.
Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L: Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 2006, 66: 18-23. 10.1158/0008-5472.CAN-04-3905.CrossRefPubMed
37.
Ren H, Chu Z, Mao L: Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 2009, 8: 1106-1112. 10.1158/1535-7163.MCT-08-0779.PubMedCentralCrossRefPubMed
Metadata
Title
Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer
Authors
Yanyan Zhou
Nanxiang Zhou
Weiyi Fang
Jirong Huo
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2010
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-5-58

Other articles of this Issue 1/2010

Diagnostic Pathology 1/2010 Go to the issue

Case Report

Pancreatic intraductal papillary mucinous neoplasm with concomitant heterotopic pancreatic cystic neoplasia of the stomach: a case report and review of the literature

Short report

Comparative proteomic analysis of normal and tumor stromal cells by tissue on chip based mass spectrometry (toc-MS)

Case Report

Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature

Research

Evaluation of neuroendocrine markers in renal cell carcinoma

Case Report

Pulmonary carcinosarcoma initially presenting as invasive aspergillosis: a case report of previously unreported combination

Research

Follicular thyroid carcinoma invades venous rather than lymphatic vessels